Company news

Hunan Nucien Pharmaceutical Co. Ltd. news in 2026

Hunan Nucien Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold

November 19, 2026

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Report for Q3 2026

October 30, 2026

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing

October 30, 2026

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold

October 23, 2026

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Amendment to the Articles of Association, Change of Legal Representative and Completion of Industrial and Commercial Registration Changes

October 23, 2026

(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital

October 9, 2026

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

September 22, 2026

Announcement on Election of New Board of Directors

September 4, 2026

Announcement on Shareholding Reduction Plan of Shareholder

September 2, 2026

Announcement on Progress of the Transfer of Certain Accounts Receivable and Related Party Transactions

August 31, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

August 30, 2026

Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing

August 25, 2026

Announcement on Appointment of General Manager

August 21, 2026

Announcement on the Receipt of Warning Letters by the Company and Relevant Responsible Persons

August 13, 2026

Announcement on Reduction of Registered Capital, Amendment of the Articles of Association, and Completion of Industrial and Commercial Registration Changes

August 10, 2026

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

July 15, 2026

Announcement on Abnormal Fluctuations in Stock Trading

July 14, 2026

Announcement on Implementing Cancellation of Repurchased Shares and Share Changes

July 8, 2026

Announcement on Receipt of Drug Registration Acceptance Notice

June 22, 2026

Announcement on Progress in the Strategic Restructuring of Controlling Shareholders

June 17, 2026

Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser Solution

June 16, 2026

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint

June 11, 2026

Announcement on Receiving the Prior Notice of Administrative Penalty

June 9, 2026

Announcement on Progress in Transfer of Partial Accounts Receivable and Related Party Transactions

June 1, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 22, 2026

Indicative Announcement on the Controlling Shareholder's Planning of Strategic Restructuring

May 14, 2026

Announcement on Changing Purpose of Repurchased Shares Canceling and Reducing Registered Capital, and Amending the "Articles of Association"

April 29, 2026

Announcement on Resignation of Core Technical Personnel

April 24, 2026

Announcement on Progress in Public Listing and Transfer of Partial Accounts Receivable

April 15, 2026

Announcement on Progress in Repurchasing Shares through Call Auction

April 1, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 27, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

February 11, 2026

Announcement on Expected Loss in Performance for 2025

January 30, 2026

Announcement on By-electing an Independent Director and Adjusting Members of Partial Special Committees

January 26, 2026

Announcement on Resignation of Independent Director

January 4, 2026